Variants of the KCNC1 gene impact K v 3.1 potassium channel function, resulting in neurodevelopmental disorders which can include progressive myoclonic epilepsy (PME) and developmental epileptic ...

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics with the potential to restore synapses that could improve the lives of patients worldwide, today ...

Please provide your email address to receive an email when new articles are posted on . The Osprey and Apteryx trials will assess QLS-111, a potassium channel modulator, in patients with glaucoma. The ...

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...

When a scrappy team of scientists joined forces in the late 1990s, they sought to identify genetic mutations that could have an outsized impact on the treatment of human disease. At the time, that ...

LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of ...

(MENAFN- EIN Presswire) EINPresswire/ -- The global ion channel modulators market is entering a decade of sophisticated molecular innovation, with its valuation projected to rise from USD 13.3 billion ...